Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Neuronetics, Inc. Common Stock

STIM

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

Last trade $1.29
Day change +$0.035 (+2.80%)
Day range $1.25 – $1.32
Volume 1,535,789
Market cap $121M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$120.6M
Price / earnings
—
Price / book
6.45×
Price / sales
0.75×
EV / sales
1×
EV / EBITDA
-13.34×

Profitability

Earnings per share
-$0.24
Return on assets
-17.49%
Return on equity
-123.36%
Dividend yield
0%

Liquidity and leverage

Debt / equity
3.3×
Current ratio
2.01×
Quick ratio
1.82×
Cash ratio
0.82×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for STIM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$41.96M$41.57M$34.45M$41.78M$37.3M$38.11M$31.98M$22.49M
Cost of revenue$20.07M$20.35M$18.3M$20.07M$20.19M$20.35M$16.24M$7.6M
Gross profit$21.89M$21.22M$16.15M$21.7M$17.11M$17.76M$15.74M$14.89M
Selling, general and administrative$20.16M$21.39M$23.79M$25.08M$22.93M$24.02M$25.14M$20.59M
Research and development$1.19M$1.34M$1.36M$1.67M$1.5M$1.8M$1.62M$5.77M
Total operating expenses$21.35M$22.72M$25.15M$26.75M$24.43M$25.82M$26.75M$26.37M
Operating income$541K-$1.5M-$9M-$5.04M-$7.32M-$8.06M-$11.01M-$11.47M
Interest expense-$2.14M-$2.13M-$2.27M-$2.32M-$2.21M-$1.97M-$1.92M-$1.76M
Income before taxes-$1.56M-$3.46M-$10.78M-$7.21M-$9.4M-$9.84M-$12.69M-$12.68M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.56M-$3.46M-$10.78M-$7.21M-$9.4M-$9.84M-$12.69M-$12.68M
Net income attributable to common shareholders-$1.69M-$3.44M-$10.79M-$7.16M-$9.05M-$10.12M-$12.68M-$12.66M
EBITDA$1.28M-$772K-$8.25M-$4.28M-$6.44M-$7.16M-$10.1M-$11.03M
Basic earnings per share-$0.02-$0.05-$0.16-$0.10-$0.13-$0.15-$0.21-$0.34
Diluted earnings per share-$0.02-$0.05-$0.16-$0.10-$0.13-$0.15-$0.21-$0.34

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

Neuronetics priced an underwritten public offering of 18.75 million shares at $1.60 per share, generating approximately $30 million in gross proceeds. The company plans to use proceeds to repay at least $15 million of its term loan with Perceptive Credit Holdings and for general corporate purposes. The offering is expected to close on November 12, 2026, contingent on satisfying customary closing conditions and amendment conditions by November 30, 2026.

Zacks Investment Research

Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates

Neuronetics (STIM) reported a quarterly loss of $0.02 per share, beating the consensus estimate of $0.08 loss by 75%, with revenues of $41.96 million exceeding expectations by 3.10%. The stock has gained 63.8% year-to-date, outperforming the S&P 500's 10.6% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Beta Bionics (BBNX) reported a quarterly loss of $0.52 per share, beating consensus estimates of $0.53 loss, with revenues of $35.51 million exceeding expectations by 0.96%. Despite the positive earnings surprise and a Zacks Rank #2 (Buy) rating, the stock has declined 32.7% year-to-date compared to the S&P 500's 12.1% gain. The company's future performance will depend on management commentary and upcoming earnings estimate revisions.

Zacks Investment Research

Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates

Integra LifeSciences reported Q3 2026 earnings of $0.59 per share, beating consensus estimates of $0.56, but revenues of $411.18 million missed expectations by 0.81%. The company received a Zacks Rank #3 (Hold) rating, suggesting market-in-line performance ahead. The Medical-Instruments industry ranks in the top 41% of Zacks industries.

Benzinga

Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan

Major M&A activity includes Unilever acquiring gummy supplements maker Grüns for $1.2 billion, Bill Ackman's Pershing Square offering $63 billion for Universal Music Group, and Capital One completing its $2.56 billion acquisition of Brex. Meanwhile, several companies face financial distress with Asend Elements and National Road Logistics filing for Chapter 11 bankruptcy, and Saks Global Enterprises restructuring debt from its Neiman Marcus acquisition.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.